3-D Matrix, Inc., based in Waltham, Massachusetts, is a wholly owned subsidiary of 3-D Matrix, Ltd., Tokyo, Japan. The 3-D Matrix Group develops and manufactures a family of peptide biomaterials under the trade name PuraMatrix® for use in clinical applications and life science research.
3-D Matrix has driven development of its technology using a “lean company” model, leveraging the activities of its founding scientists at MIT, the company’s multiple collaborations with leading companies, outsourced manufacturing to contract facilities, and distribution agreements for its commercial products. This structure has proven extremely efficient at driving pre-clinical proof-of-concept studies while commercializing products with the life science and drug discovery research communities. The company intends to build its business development and scientific staff to mirror the near-term opportunities driven by partnerships as well as internal developments.
Marc Rioult, PhD/MBA, has developed for over twelve years technologies, startups, and companies in the biomedical field but also in nanotechnology, software, chemicals, and microfluidics. Before joining 3-D Matrix, Dr. Rioult has worked at MIT as a Technology Licensing Officer, for two consulting firms engaged in IP and technology transactions for clients ranging from startups to Fortune 500 companies, and co-managed a software company after leaving academic research in neuroscience. He serves on the boards of several domestic and foreign companies and academic institutions.